<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543127</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-10</org_study_id>
    <nct_id>NCT00543127</nct_id>
  </id_info>
  <brief_title>Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol</brief_title>
  <official_title>A Randomized, Multicentral, Phase III Study of Parallel Groups to Compare the Efficiency and Tolerance of Fulvestrant Administered for Three Years in Combination With Anastrozol for 5 Years Versus Anastrozol for 5 Years as Adjuvant Hormonotherapy in Postmenopausal Women With Early Breast Cancer and + HRs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postmenopausal women with hormone receptor positive and negative Her2 tumours.

      Estimation of the 5-year disease-free survival in the control arm is 80%. The experimental
      arm is expected to increase the 5-year disease-free survival by 4% (up to 84%). With an alpha
      error of 0.05 and 80% power, 1445 patients per arm are needed. Assuming a 10%
      post-randomization drop-out, 3180 patients in total are needed.

      Before randomization, the patients will be stratified according to the center, positive
      nodes(0 vs. 1-3 vs. ≥4), previous chemotherapy (yes vs no) and hormonal receptors status.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unjustified decision of company that funded the trial.
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare free disease survival of patients treated with Fulvestrant for 3 years and anastrozol for 5 years versus free disease survival of patients treated with anastrozol for 5 years.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare breast cancer specific survival between both arms of treatment. To compare overall survival between both arms of treatment. To compare safety profile and tolerance between both arms od treatment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">872</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant charge dose days 0,14, 28 (250 mg) and later each 28 days concomitant with anastrozol (1 mg daily) for the three first years followed by 2 years with anastrozol (1mg daily)alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozol 1 mg daily for 5 yeras.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant + anastrozol</intervention_name>
    <description>500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral anastrozol per day during 5 years.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozol</intervention_name>
    <description>1 mg oral Anastrozol per day during 5 years.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written signed informed consent.

          2. Breast cancer histologically confirmed.

          3. Stages I, II, IIIA of invasive breast cancer. Patients must comply with one of the
             following characteristics: N+, T &gt; 2 cm.

          4. Mastectomy or lumpectomy with free margins + radiotherapy, axilar node dissection or
             centinel node dissection.

          5. Positive hormonal receptors (ER+ and/or PgR+) determined at a central laboratory.

          6. Negative HER2 (defined as IHQ 0 or 1+ or negative FISH when IHQ 2+ or 3+).

          7. Postmenopausal women (woman complies with one of the following criteria: age ≥ 60
             years, age ≥ 45 years and amenorrhea, amenorrhea ≥ 12 months and undamaged uterus,
             bilateral ovariectomy, FSH and estradiol level into postmenopausal range (using local
             ranges).

          8. ECOG = 0, 1 or 2.

          9. Age &gt; 18 years.

        Exclusion Criteria:

          1. Metastatic disease or invasive bilateral breast cancer.

          2. Negative ER and PgR breast cancer.

          3. Treatment with a not approved or experimental drug within 4 weeks before
             randomization.

          4. Current or previous malignant process within the last 5 years (different from breast
             cancer or basocelular carcinoma or escamocelular of the skin or cervix carcinoma in
             situ).

          5. Pregnant or lactating women. 6. Concurrent hormone replacement therapy and other
             hormonal agents (raloxifen, tamoxifen,etc.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Martín Jiménez, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Ramos Vázquez, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Oncológico de Galicia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Ruiz Borrego, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Moreno, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jerez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Manuel Baena Cañada, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Antolín, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Juan Canalejo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Alonso Romero, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angels Arcusa Lanza, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorci Sanitari de Terrasa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Moreno, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Municipal de Badalona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Álvarez, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Carlos Toral, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Torrevieja</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Calvo, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Madrid Norte Sanchinarro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Sanchez Rovira, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Jaén</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Salvador Bofill, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Valme</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Carabantes, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Alba, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Victoria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Bayo, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Especialidades Juan Ramón Jimenez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Florián, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Comarcal de Barbastro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Antón, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Ignacio Mayordomo, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignacio Pelaez, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cabueñes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat Muñoz, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia González, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Mutua de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Lluch, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Godes, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustín Barnadas, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Creu i San Pau.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Cassinello, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Guadalajara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Ángel Seguí, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Álvaro Rodriguez Lescure, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Elche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Ignacio Chacón, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Salud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar López, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>hospital Ntra. Sra. de la Candelaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adolfo Murias, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Insular de las Palmas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Llombart, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova de Lérida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana de Juan, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ángel Guerrero, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amparo Oltra, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de los Lirios</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan de la Haba, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Provincial Reina Sofía</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Breast Cancer Research Group (GEICAM)</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 13, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

